Standard

Long-term vs Short-term Therapy With Vitamin K Antagonists for Symptomatic Venous Thromboembolism. / Middeldorp, Saskia; Hutten, Barbara A.

In: JAMA, Vol. 314, No. 1, 2015, p. 72-73.

Research output: Contribution to journal › Review article › Academic › peer-review

Harvard

Middeldorp, S & Hutten, BA 2015, 'Long-term vs Short-term Therapy With Vitamin K Antagonists for Symptomatic Venous Thromboembolism', JAMA, vol. 314, no. 1, pp. 72-73. https://doi.org/10.1001/jama.2015.2693

APA

Middeldorp, S., & Hutten, B. A. (2015). Long-term vs Short-term Therapy With Vitamin K Antagonists for Symptomatic Venous Thromboembolism. JAMA, 314(1), 72-73. https://doi.org/10.1001/jama.2015.2693

Vancouver

Middeldorp S, Hutten BA. Long-term vs Short-term Therapy With Vitamin K Antagonists for Symptomatic Venous Thromboembolism. JAMA. 2015;314(1):72-73. doi: 10.1001/jama.2015.2693

Author

Middeldorp, Saskia ; Hutten, Barbara A. / Long-term vs Short-term Therapy With Vitamin K Antagonists for Symptomatic Venous Thromboembolism. In: JAMA. 2015 ; Vol. 314, No. 1. pp. 72-73.

BibTeX

@article{b60ebfcc4baa4ab3acbf9a6aa41695f2,
title = "Long-term vs Short-term Therapy With Vitamin K Antagonists for Symptomatic Venous Thromboembolism",
abstract = "CLINICAL QUESTION Is long-term (>= 3 months) vs short-term therapy with vitamin K antagonists (VKAs) associated with differences in the incidence of recurrent venous thromboembolism (VTE), major bleeding, and mortality in patients with symptomatic VTE? BOTTOM LINE Long-term treatment with VKAs is associated with a reduced risk for recurrent VTE and an increased risk for major bleeding compared with short-term treatment in patients with VTE, but is not associated with differences in mortality",
author = "Saskia Middeldorp and Hutten, {Barbara A.}",
year = "2015",
doi = "10.1001/jama.2015.2693",
language = "English",
volume = "314",
pages = "72--73",
journal = "JAMA",
issn = "0098-7484",
publisher = "American Medical Association",
number = "1",

}

RIS

TY - JOUR

T1 - Long-term vs Short-term Therapy With Vitamin K Antagonists for Symptomatic Venous Thromboembolism

AU - Middeldorp, Saskia

AU - Hutten, Barbara A.

PY - 2015

Y1 - 2015

N2 - CLINICAL QUESTION Is long-term (>= 3 months) vs short-term therapy with vitamin K antagonists (VKAs) associated with differences in the incidence of recurrent venous thromboembolism (VTE), major bleeding, and mortality in patients with symptomatic VTE? BOTTOM LINE Long-term treatment with VKAs is associated with a reduced risk for recurrent VTE and an increased risk for major bleeding compared with short-term treatment in patients with VTE, but is not associated with differences in mortality

AB - CLINICAL QUESTION Is long-term (>= 3 months) vs short-term therapy with vitamin K antagonists (VKAs) associated with differences in the incidence of recurrent venous thromboembolism (VTE), major bleeding, and mortality in patients with symptomatic VTE? BOTTOM LINE Long-term treatment with VKAs is associated with a reduced risk for recurrent VTE and an increased risk for major bleeding compared with short-term treatment in patients with VTE, but is not associated with differences in mortality

U2 - 10.1001/jama.2015.2693

DO - 10.1001/jama.2015.2693

M3 - Review article

C2 - 26151268

VL - 314

SP - 72

EP - 73

JO - JAMA

JF - JAMA

SN - 0098-7484

IS - 1

ER -

ID: 2649606